Dan Peer is a Professor and the Director of the Laboratory of Precision NanoMedicine at Tel Aviv University (TAU). He is the Director of a national nanomedicine initiative project. He is also the Director of Leona M. and Harry B. Helmsley Nanotechnology Research Fund and the Chair of Tel Aviv University Cancer Biology Research Center; the biggest Cancer Center in Israel that includes 17 affiliated hospitals. Prof. Peer’s work was among the first to demonstrate systemic delivery of RNA molecules using targeted nanocarriers to the immune system and he pioneered the use of RNA interference (RNAi) for in vivo validation of new drug targets within the immune system that has enormous implications in Cancer and inflammation. Prof. Peer and his team have done innovative and groundbreaking work in cancer, mostly in brain tumors (Glioblastoma), Ovarian Cancer, and a set of blood cancers (Mantle Cell Lymphoma, Multiple Myeloma and Chronic Lymphocytic Leukemia). His work is published in premier scientific journals and he is the editor and author of several books in the field of nanomedicine. In addition, he is an associate editor of Journal of Controlled Release, and a member of the editorial boards of numerous journals including Cancer Letters and ACS Bioconjugate Chemistry. Prof. Peer is a past President of the Israeli Chapter of the Controlled Release Society, and a Member of the Israel Young Academy of Sciences